Protocol of a randomized trial of acceptance and commitment therapy for fatigue interference in metastatic breast cancer by Mosher, Catherine E. et al.
1 
Protocol of a Randomized Trial of Acceptance and Commitment Therapy for Fatigue 
Interference in Metastatic Breast Cancer 
Catherine E. Mosher, Ph.D
a,*







Kathy D. Miller, M.D
b 
kathmill@iu.edu, Tarah J. Ballinger,
M.D
b
tarahb@iu.edu, Anna Maria Storniolo, M.D
b
astornio@iu.edu, Bryan P. Schneider,
M.D
b
bpschnei@iu.edu, Erin V. Newton, M.D
b
evnewton@iu.edu, Victoria L. Champion, Ph.D.,
RN, FAAN
c




Department of Psychology, Indiana University-Purdue University Indianapolis, 402 North 
Blackford Street, LD 124, Indianapolis, IN 46202, USA 
b
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana Cancer 
Pavilion, 535 Barnhill Drive, Suite 473, Indianapolis, IN 46202, USA 
c
Indiana University School of Nursing, 1111 Middle Drive, NU 340G, Indianapolis, IN 46202, 
USA 
d
Indiana University School of Medicine, Center for Health Services Research, Regenstrief 
Institute, 1101 W. 10
th
 Street, Indianapolis, IN 46202, USA.
*
Correspondence to: Catherine E. Mosher, Ph.D., Department of Psychology, Indiana University-
Purdue University Indianapolis, 402 North Blackford Street, LD 124, Indianapolis, IN 46202, 
USA.   
Abstract 
Fatigue interference with activities, mood, and cognition is one of the most prevalent and 
distressing concerns of metastatic breast cancer patients. To date, there are no evidence-based 
interventions for reducing fatigue interference in metastatic breast cancer and other advanced 
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cancer populations. In pilot studies, Acceptance and Commitment Therapy (ACT) has shown 
potential for reducing symptom-related suffering in cancer patients. The current Phase II trial 
seeks to more definitively examine the efficacy of telephone-based ACT for women with 
metastatic breast cancer who are experiencing fatigue interference. In this trial, 250 women are 
randomly assigned to either the ACT intervention or an education/support control condition. 
Women in both conditions attend six weekly 50-minute telephone sessions. The primary aim of 
this study is to test the effect of telephone-based ACT on fatigue interference. Secondary 
outcomes include sleep interference, engagement in daily activities, and quality of life. 
Outcomes are assessed at baseline, 2 weeks post-intervention, and 3 and 6 months post-
intervention. This trial also examines whether increases in psychological flexibility, defined as 
full awareness of the present moment while persisting in behaviors aligned with personal values, 
account for the beneficial effect of ACT on fatigue interference. After demonstrating ACT’s 
efficacy, the intervention can be widely disseminated to clinicians who care for metastatic breast 
cancer patients. Our findings will also inform future ACT trials with various cancer populations 
and functional outcomes.   
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Fatigue is a prevalent, persistent, debilitating symptom in metastatic breast cancer (MBC) 
patients [1-3]. Moderate-to-severe fatigue is reported by over 50% of MBC patients [1, 2]. 
Fatigue frequently co-occurs with a number of symptoms, such as sleep disturbance, cognitive 
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concerns, anxiety, and depressive symptoms [4, 5], resulting in impaired daily activities [1, 5, 6]. 
Evidence-based interventions for managing fatigue in MBC and other advanced cancer 
populations are lacking [7-9]. A Cochrane meta-analysis of pharmacologic interventions for 
fatigue in advanced cancer and other palliative care patients characterized the evidence as 
inconclusive and highlighted the small, heterogeneous samples in many studies [7]. Furthermore, 
of the five psychotherapy trials for MBC patients targeting fatigue [9], only a trial of year-long 
supportive-expressive group therapy effectively reduced fatigue [10]; importantly, this finding 
was not replicated by others [11]. Innovative approaches are therefore needed to reduce fatigue-
related suffering and interference with functioning. 
One behavioral intervention that shows potential for reducing symptom-related suffering in 
cancer patients is Acceptance and Commitment Therapy (ACT) [12, 13]. Rather than focusing 
on symptom reduction, the goal of ACT is to increase psychological flexibility so that difficult 
internal experiences (e.g., physical symptoms, feelings, thoughts) interfere less with meaningful 
activities [14, 15]. Psychological flexibility is comprised of mindfulness/acceptance processes 
(i.e., nonjudgmental attention to the present moment) and commitment/behavior change 
processes (i.e., identifying personal values such as family or work and taking action steps 
consistent with these values) [15]. ACT has been shown to reduce distress and pain interference 
in patients with chronic pain [16-19] and has been tested in pilot trials with cancer patients [13, 
14, 20-22]. In our pilot RCT, MBC patients were randomized to six telephone sessions of either 
ACT or time-equivalent education/support [23]. ACT showed strong evidence of feasibility and 
promise with respect to fatigue and sleep interference with activities, mood, and cognition. 
Feasibility was demonstrated by the eligibility screening rate (64% of reached patients agreed to 
be screened) and the retention rate (83% [39/47] at 8 weeks post-intervention). 
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The primary aim of this NIH-funded Phase II RCT is to more definitively examine the 
efficacy of our telephone-based ACT intervention for women with MBC who have fatigue 
interference. We hypothesize that ACT will lead to an improved primary outcome of fatigue 
interference as compared to time-equivalent education/support. Our second aim is to test the 
effects of telephone-based ACT on the secondary outcomes of sleep interference, engagement in 
daily activities, and quality of life. We hypothesize that ACT will lead to superior secondary 
outcomes relative to education/support. Our third aim is to test the hypothesis that increased 
psychological flexibility will mediate ACT’s effect on fatigue interference. Our fourth aim is to 
explore changes in the two core aspects of psychological flexibility (i.e., mindfulness/acceptance 
and commitment/behavior change processes) as mediators of ACT’s effect on fatigue 
interference. The current paper describes the rationale, design, methods, and statistical plan for 
this RCT that aims to address a critical gap in comprehensive, evidence-based care for women 
with MBC. 
2. Materials and Methods
2.1. Overview of study design 
This Phase II RCT tests the effects of telephone-based ACT on fatigue interference and 
related outcomes in women with MBC. Our recruitment goal is 250 patients with moderate-to-
severe fatigue interference. We recruited about six patients per month over 8 months in our pilot 
[23]. Assuming a similar recruitment rate, we will recruit 250 patients over 3.5 years. Patients 
are randomized to six weekly 50-minute telephone sessions of ACT or six weekly 50-minute 
telephone sessions of education/support. Outcomes are assessed at baseline, 2 weeks post-
intervention (primary endpoint), and 3 and 6 months post-intervention. This trial was registered 
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in clinicaltrials.gov (NCT03998618) and approved by the Indiana University Institutional 
Review Board. 
2.2. Participant eligibility criteria 
Eligible patients meet the following inclusion criteria: a) > 18 years old, b) at least 3 weeks 
post-diagnosis of Stage IV breast cancer as ascertained through medical records and consultation 
with the attending oncologist, and c) moderate to severe fatigue interference (i.e., mean score 
>2.5 on the Fatigue Interference subscale of the Fatigue Symptom Inventory [FSI]) [24, 25]. The
clinical validity of this cut point is supported by our pilot research with MBC patients. Exclusion 
criteria include: a) significant cognitive impairment (dementia/delirium, psychosis) as 
ascertained by a medical record review and administration of a mental status questionnaire [26], 
b) patient-reported Eastern Cooperative Oncology Group (ECOG) score > 2 (spend most of the
day in bed or chair) [27], c) enrolled in hospice, d) lack of English fluency, e) male, and f) no 
working phone service. Those with an ECOG score above 2 are excluded, as the ACT 
intervention is designed for those who can engage in at least moderate levels of activity. 
2.3. Recruitment  
Under an IRB-approved waiver of HIPAA authorization, study staff search electronic health 
records for patients with a diagnosis of MBC, along with the name of their primary oncologist. 
The primary oncologist reviews patient lists and indicates those whom we may contact about 
participation. Potentially eligible women are mailed a study introductory letter along with a 
consent form. The letter includes a phone number for those who have questions or wish to opt 
out of further contact from the study team. 
A research assistant (RA) calls all patients who do not opt out approximately 1 to 2 weeks 
after the letter is mailed. The RA describes the study as outlined in the consent form, answers 
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questions, and administers a screening assessment (i.e., Fatigue Interference subscale of FSI [24, 
25], ECOG [27], and mental status questionnaire [26]) with the patient’s permission. Eligible and 
interested patients provide consent for study participation over the phone under a waiver of 
documentation of written informed consent. 
2.4. Randomization and blinding  
Following baseline assessments, patients are randomly assigned to ACT or education/support 
using stratified block randomization to balance the groups by age (<65 yrs. vs. ≥65 yrs.) and 
performance status (patient-reported ECOG scores 0 or 1 vs. 2 [27]). We are stratifying 
randomization by performance status because it is a key factor in MBC treatment decisions [28]. 
The statistician uses the R package ―blockrand‖ [29, 30] to generate random assignments within 
blocks. Randomly varying block sizes of 2, 4, 6, and 8 are used to maintain allocation 
concealment and assure balanced allocation to study conditions. Following randomization, 
intervention assignments are identifiable to patients, interventionists, and staff mailing 
intervention materials. Other investigators, data monitoring committee members, outcome 
assessors, and data analysts are blinded throughout the trial. 
2.5. Interventions 
2.5.1. Acceptance and Commitment Therapy (ACT) 
Study team members developed the ACT manual, which was informed by literature on 
fatigue and related symptoms in MBC patients [1, 2, 4], the ACT model [12, 15], previous ACT 
trials with patients with cancer and other chronic conditions [14, 17, 18, 20, 31, 32], and our 
clinical experience. Table 1 provides a summary of the intervention components. Grounded in 
the ACT model [15], the intervention is designed to reduce fatigue interference by increasing 
psychological flexibility, consisting of mindfulness/acceptance processes and 
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commitment/behavior change processes (see Figure 1: Conceptual Model). The 
mindfulness/acceptance component of psychological flexibility is targeted through mindfulness 
practices that facilitate non-reactive acceptance of fatigue-related thoughts, emotions, and bodily 
sensations. Willingness to experience the present moment courageously and flexibly is 
emphasized. Additionally, the commitment/behavior change component of psychological 
flexibility is targeted through identifying deeply held values (e.g., being a loving, engaged 
parent) and making behavior changes consistent with these values. Weekly value-based action 
goals are in the SMART format (Specific, Measurable, Achievable, Relevant, and Time-Bound). 
Thus, ACT emphasizes living consistently with one’s values even when fatigued rather than 
focusing one’s cognitive and physical energies on controlling fatigue. Although all patients learn 
the same set of skills, sessions are tailored to their unique cancer experience and other 
challenges. The therapist administers three items from the Fatigue Symptom Inventory (i.e., 
average fatigue and fatigue interference with general activity and enjoyment of life) [24, 25], two 
PROMIS anxiety items [33], and two PROMIS depression items [33] during each session. These 
reports allow the therapist to monitor fatigue and distress. The therapist also assesses and records 
the patient’s home practice of mindfulness and other skills and ends with a discussion of practice 
for the week ahead. Handouts summarizing the topics of each session and recordings that our 
team developed to guide mindfulness practices are sent to patients. 
2.5.2. Education/Support 
The education/support condition was tested in our pilot feasibility trial [23] and is similar to 
controls in other cancer trials [34, 35]. Patients randomized to this condition discuss their 
concerns, including symptoms and other cancer-related stressors, with a therapist providing 
psychological support. The therapist directs patients to resources for practical and health 
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information and contact information for psychosocial services. Additionally, the same fatigue, 
depression, and anxiety assessments as those in the ACT condition are completed during each 
session [24, 25, 33]. Table 1 provides a summary of the education/support components. Sessions 
include an orientation to the patient’s medical center and treatment team, education regarding 
common quality-of-life concerns and symptoms experienced by cancer patients, and an overview 
of medical center and community resources for addressing these concerns. Therapists also 
describe resources for addressing financial concerns and methods of evaluating health 
information available via the Internet and other modalities. Education/support patients receive 
handouts summarizing the topics of each session and are asked to review them as homework. 
ACT concepts are not discussed. 
2.5.3. Intervention training and supervision 
Therapists are doctoral level psychologists or advanced doctoral students in clinical 
psychology with extensive training and experience delivering ACT or supportive counseling. 
Different therapists deliver each intervention to prevent cross-contamination between study 
conditions. Therapists received initial education in MBC diagnosis and treatment, psychological 
distress, and either ACT or supportive counseling techniques with training protocols developed 
in previous studies. Initial training also included role-plays of sessions detailed in manuals. All 
sessions are digitally recorded, and licensed psychologists and advanced doctoral students in 
clinical psychology randomly select recordings to review for adherence to the manual using 
checklists developed in our pilot work. Individuals monitoring adherence have expertise in ACT 
or supportive counseling techniques and received training in fidelity monitoring. During regular 
supervision with therapists, treatment adherence scores (number of required topics and exercises 
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covered in each session/total number of fidelity criteria) are provided and treatment fidelity 
issues are discussed. Therapists implement the feedback in subsequent sessions. 
2.6. Retention 
A number of strategies are used to increase study retention. All study staff, including RAs 
and therapists, have been trained to clearly communicate expectations to patients and to offer the 
option of completing follow-ups if they do not adhere to the intervention. Use of the telephone 
for all assessments and the intervention reduces barriers to participation for rural residents and 
those with low incomes. Text, phone, or email reminders are sent to patients prior to 
appointments. Patients receive $40 in gift cards to a major retailor for participating in each of the 
four assessments, for a possible total of $160 in gift cards.  
2.7. Study measures and data collection schedule 
Study measures and the data collection schedule are found in Table 2. Measures equate to a 
35-minute baseline assessment and three, 30-minute follow-up assessments conducted by 
research assistants blind to study condition. All measures have evidence of reliability and 
validity in cancer patients. 
2.7.1. Primary outcome: fatigue interference 
The primary outcome measure is the 7-item Fatigue Interference subscale of the FSI [24, 25]. 
Items are rated on 11-point scales (0 = no interference; 10 = extreme interference) that assess the 
extent to which fatigue in the past week interfered with general level of activity, ability to bathe 
and dress, normal work activity (including housework), ability to concentrate, relations with 
others, enjoyment of life, and mood. 
2.7.2. Secondary outcomes 
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Sleep interference is assessed with the 8-item Patient-Reported Outcomes Measurement 
Information System (PROMIS) sleep-related impairment measure [36, 37]. This measure 
evaluates the perceived interference of sleep problems with activities, mood, and cognition. 
Engagement in daily activities is assessed with the 6-item PROMIS short-form measure of 
ability to participate in social roles and activities [38]. The items, which are reverse-coded, 
measure difficulty engaging in social and recreational activities as well as usual work (including 
housework). Quality of life is measured with the 27-item Functional Assessment of Cancer 
Therapy-General (FACT-G), consisting of four subscales: Physical Well-Being, Social/Family 
Well-Being, Emotional Well-Being, and Functional Well-Being [39]. An overall score is 
computed to represent general quality of life. 
2.7.3. Mediators 
Psychological flexibility, as measured by the 7-item Acceptance and Action Questionnaire-II 
(AAQ-II) [40], is assessed as a hypothesized mediator of the intervention’s effect on fatigue 
interference. The two core components of psychological flexibility are also assessed as 
exploratory mediators. First, mindfulness/acceptance is measured by the 10-item Cognitive and 
Affective Mindfulness Scale-Revised (CAMS-R) [41]. The scale provides a comprehensive 
assessment of mindfulness processes, including attention, present-focus, awareness, and 
acceptance/non-judgement. Second, commitment/behavior change is measured by the 5-item 
Value Progress subscale of the Valuing Questionnaire [42]. This subscale assesses progress in 
living consistently with personal values. 
2.7.4. Descriptive variables 
To characterize the sample, we assess standard demographics and medical factors. Self-
reported medical comorbidities are assessed via a checklist of nine chronic health conditions 
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[43]. Functional status is measured with the 1-item Patient Generated Subjective Global 
Assessment (PG-SGA), a patient-reported version of the ECOG score [27]. Cancer information, 
such as time since diagnosis and treatments, is assessed via chart review. Additionally, seven 
self-report items assess physical and mental healthcare use, including outpatient and emergency 
room visits, use of alternative healthcare services, and (at baseline only) prior mindfulness 
training [43, 44]. Patients also report their prescribed and over-the-counter medications. Finally, 
measures of symptom severity are administered. Fatigue severity and frequency are measured 
with six items from the FSI [24, 25], and sleep disturbance, cognitive concerns, anxiety, and 
depressive symptoms are each assessed with a 6-item PROMIS measure [33, 36, 37, 45-47]. Pain 
is assessed with 3-item and 4-item PROMIS measures of severity and interference, respectively 
[45, 48]. The extent to which hot flashes interfere with aspects of quality of life is evaluated with 
the 10-item Hot Flash Related Daily Interference Scale [49]. 
3. Statistical Analyses  
3.1. Preliminary analyses 
Distributional issues. Univariate and descriptive analyses will be performed on all dependent 
variables, and if necessary, normalizing and/or variance stabilizing transformations will be 
applied to the data before inferential analyses are undertaken. Missing data/attrition. We 
anticipate some missing data due to participant death, medical factors, and other reasons. For 
individuals who complete the first assessment but withdraw from the study, we will examine 
demographic, medical, and symptom factors that might be predictive of dropout using logistic 
regression. In the analyses for Aims 1 and 2 described below, all randomized participants will be 
included in intent-to-treat analyses [50], as the aims are concerned with the impact of the 
intervention on outcomes regardless of study completion status. Second, for participants who 
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miss assessments, it is possible that attrition may be related to the study condition to which they 
have been assigned. We plan to use the random effects pattern-mixture model proposed by 
Hedeker and Gibbons [51] to address missing data. Analyses of potential covariates. Because 
patients will be randomly assigned to study conditions, significant differences in baseline values 
of all measured variables are not expected. Even so, we will assess for differences in baseline 
factors (e.g., demographic, medical and healthcare use variables, symptom levels) between study 
conditions [52]. Any differences will be taken into account when interpreting results, and factors 
that differ between the groups will be included as covariates in sensitivity analyses. 
3.2. Analysis for aim 1  
A linear mixed-model repeated measures approach will be used to test the hypothesis that 
ACT will improve fatigue interference as compared to the education/support condition. The 
model will include the main effect of time (as categorical) and study group (ACT vs. 
education/support) and the time-by-study group interaction. A treatment effect will be evidenced 
by a significant interaction between time and study group. If the treatment effect is significant, 
follow-up tests will be conducted to examine group differences at each follow-up, controlling for 
the outcome at baseline.  
Our sample size is calculated based on the estimated difference between study conditions 
(ACT vs. education/support) on the primary outcome of fatigue interference at 2 weeks post-
intervention. In our pilot study, we found a moderate effect (d = -.30) of study condition on 
fatigue interference at 1 month post-intervention [23]. It should be noted that only about half of 
the pilot sample had elevated fatigue interference at baseline (unlike the present study, the pilot 
study did not require all eligible patients to have clinically significant levels of fatigue 
interference); thus, the effect size is likely to be higher in the present study where the sample will 
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have uniformly elevated fatigue interference at study entry. Indeed, among patients with 
moderate to severe baseline fatigue interference in our pilot study, we found a strong effect (d = -
.59) of study condition on fatigue interference at 1 month post-intervention. Thus, we 
conservatively estimate a medium effect size of d = -.40 at 2 weeks post-intervention. With a 
sample size of 198 patients at 2 weeks post-intervention (assuming 21% attrition based on our 
pilot [23]), we will have 80% power (p = .05, two-tailed) to detect a Cohen’s d of -.40 in a linear 
mixed model [53]. At the final, 6-month follow-up with a sample size of 163 (assuming 35% 
attrition), we will have 80% power (p = .05, two-tailed) to detect a Cohen’s d of -.44 [53]. The 
estimated attrition is based on our promising feasibility data for telephone-based ACT [23], use 
of telephone assessments to maximize compliance, and MBC survival rates [54]. 
We will use established minimal clinically important differences (MCIDs) on the FACT-G 
total score and subscale scores as anchors for determining a MCID in fatigue interference. 
MCIDs for MBC and other cancer patients are 2-point differences on the FACT-G subscale 
scores and a 5-point difference on the FACT-G total score, which fall in the range of .3 to .5 SDs 
[55, 56]. We will calculate mean changes in fatigue interference from baseline to 2 weeks post-
intervention corresponding with established MCIDs on the FACT-G. Then effect sizes for these 
mean changes will be computed. Although MCIDs have yet to be determined for measures of 
fatigue interference, guidelines on MCIDs for pain interference and quality-of-life measures 
suggest that an effect size of .5 (.5 SD) is clinically meaningful [57-60]. The current trial is 
powered to detect this effect size. 
3.3. Analysis for aim 2 
Linear mixed models will be run to test the hypothesis that ACT will improve the secondary 
outcomes of sleep interference, engagement in daily activities, and quality of life as compared to 
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the education/support condition. Each model will include the main effect of time (as categorical) 
and study group and the time-by-study group interaction. A treatment effect will be evidenced by 
a significant interaction between time and study group. The Sidak adjustment for correlated 
multiple outcomes will be used to control the familywise Type I error rate. If treatment effects 
are significant, follow-up tests will be conducted to examine group differences at each follow-up, 
controlling for the outcome at baseline. 
3.4. Analysis for aim 3 
The PROCESS macro developed by Andrew Hayes [61] will be used to test the hypothesis 
that increased psychological flexibility will mediate the effect of ACT on fatigue interference. 
The macro employs ordinary least squares regression. Bootstrapped confidence intervals will be 
computed for the indirect effect of study group on fatigue interference at 2 weeks post-
intervention (via change in psychological flexibility over the same time period). Each analysis 
will control for baseline levels of the mediator and outcome. We tested for mediation at 2 weeks 
because this is the primary endpoint.  
3.5. Analysis for aim 4 
The PROCESS macro [61] will be used to explore the extent to which changes in 
mindfulness/acceptance and commitment/behavior change processes mediate (uniquely and 
collectively) the effect of ACT on fatigue interference. Both potential mediators will be entered 
into the same model. Bootstrapped confidence intervals will be computed for the indirect effect 
of study group on fatigue interference at 2 weeks post-intervention (via change in 
mindfulness/acceptance and commitment/behavior change processes over the same time period). 
The analysis will control for baseline levels of the mediators and outcome. 
3.6. Exploratory analyses 
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To inform future research, we will explore the extent to which sociodemographics (e.g., age, 
education) and clinical characteristics (e.g., cancer treatments, baseline severity of fatigue and 
other symptoms, healthcare use) moderate the effects of ACT on primary and secondary 
outcomes. For these analyses, we will use linear mixed modeling at a two-sided significance 
level of 0.05. Preliminary findings or hypotheses generated from these moderation analyses will 
be further tested in a future trial. 
4. Discussion 
The current trial addresses the top-rated concern of MBC patients—fatigue interference with 
activities, mood, and cognition [1, 3]. Fatigue has a substantial negative impact on their daily 
activities [1, 5]. Evidence-based interventions for fatigue interference are lacking. The ACT 
model [15] and our pilot data [23] provide strong justification for the current trial. In our pilot 
RCT, telephone-based ACT was highly feasible and acceptable to MBC patients and had a 
moderate effect on fatigue interference relative to an education/support condition; an even larger 
effect was observed in the subsample with elevated baseline fatigue interference [23]. To our 
knowledge, there is only one published large-scale trial of ACT in cancer, which focused on 
health behavior change in colorectal cancer survivors [62].  
ACT is well-suited to address fatigue interference in cancer patients, as it emphasizes 
acceptance of the present moment (mindfulness), including internal experiences such as fatigue, 
and engagement in activities consistent with personal values [12]. The use of a fatigue 
interference inclusion criterion allows us to target those most in need of intervention—an 
approach rarely used in the broader literature on behavioral interventions for fatigue [63]. 
Another noteworthy feature of this trial is that it tests theory-driven mediators of ACT’s effects. 
Only 3% of psychosocial intervention trials in cancer have analyzed potential mediators of 
16 
 
intervention effects [64]. According to the ACT model, increased psychological flexibility is the 
primary mechanism underlying the beneficial health effects of ACT [15]. The core components 
of psychological flexibility are mindfulness/acceptance processes and commitment/behavior 
change processes. In prior studies with adults, psychological flexibility mediated the effects of 
ACT on mental health outcomes [65, 66]. If increases in overall psychological flexibility mediate 
ACT’s effect on fatigue interference, then this finding would support a key aspect of the ACT 
model [15].  
Additionally, we will explore whether change in the aforementioned core components of 
psychological flexibility mediate ACT’s effect on fatigue interference. If our analysis shows that 
one component is driving ACT’s effect, then the intervention could be modified in future trials to 
focus on this mechanism. For example, if commitment/behavior change processes more strongly 
mediate ACT’s effect than does mindfulness/acceptance, this would provide a rationale for 
emphasizing these processes in future trials. 
Our ability to demonstrate ACT’s efficacy will lead to dissemination of this intervention to 
clinicians serving MBC patients, thereby addressing a critical gap in the evidence-based care of 
this rapidly growing population. This trial will also lay the groundwork for further application 
and testing of ACT on different functional outcomes and with a wide range of cancer 
populations. 
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Summary of Core Components of Each Intervention Condition 
 
Acceptance and Commitment Therapy 
 
Education/Support 
 Identify current attempts to control 
fatigue and their impact on quality of 
life 
 Practice mindfulness with the 
therapist during sessions and at home 
(e.g., awareness of the breath, body 
scan, noticing sounds).  
 Practice cognitive defusion—learning 
to notice thoughts, feelings, and 
symptoms rather than being 
overwhelmed by them (e.g., 
passengers on the bus metaphor) 
 Observe and detach from fatigue and 
related thoughts and emotions to 
cultivate a transcendent sense of self 
from which to observe and accept 
changing experience. Willingness to 
experience the present moment with 
courage and flexibility is emphasized.  
 Identify key values (e.g., being a 
 Orient patient to the medical center and 
treatment team; overview of quality of life 
concerns and discussion of physical quality 
of life and symptoms 
 Discuss common social challenges (e.g., 
talking with children about cancer and 
employment issues); tips on managing 
household challenges when ill; referral to 
resources for addressing social challenges 
 Discuss common emotional responses to 
cancer, including anxiety and depressive 
symptoms, and cognitive changes following 
cancer treatment; referral to mental health 
services 
 Describe common financial concerns related 
to cancer and its treatment; referral to 
resources for addressing financial challenges 
 Methods of evaluating health information on 
the Internet and other modalities  
 Review of prior session topics and referral to 
28 
 
loving partner, giving to one’s 
community) 
 Goal setting and practice of value-
based actions  






Table 2      
Measures and Timing of Data Collection 







Primary outcome:      
Fatigue interference Fatigue interference subscale of 
FSI 
   
Secondary outcomes:      
Sleep interference PROMIS short-form sleep-
related impairment measure 
   
Engagement in daily activities PROMIS short-form measure of 
ability to participate in social 
roles and activities 
   
Quality of life FACT-G    
Hypothesized mediator:      
Psychological flexibility Acceptance and Action 
Questionnaire-II 
   
Exploratory mediators:      
Mindfulness/Acceptance Cognitive and Affective 
Mindfulness Scale-Revised 
   
Commitment/Behavior change Values Progress subscale of 
Valuing Questionnaire 
   
Demographic and medical factors: 
     Sociodemographics Sociodemographics  
Medical comorbidity Checklist of 9 conditions     
Functional status Patient-reported ECOG    
Cancer information (e.g., date of 
diagnosis, cancer treatments) 
Chart review    
Physical and mental healthcare 
use 
Healthcare use interview    
Medications Medication interview    
Severity of symptoms:      
Fatigue severity, sleep 
disturbance, cognitive concerns, 
anxiety, depressive symptoms, 
pain severity and interference, and 
hot flash interference 
Fatigue severity and frequency 
items from FSI; PROMIS short-
form measures of sleep 
disturbance, cognitive concerns, 
anxiety, depression, and pain 
   
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severity and interference; Hot 
Flash Related Daily Interference 
Scale 
Note. FSI = Fatigue Symptom Inventory; PROMIS = Patient-Reported Outcomes Measurement Information System; FACT-G = Functional Assessment of 




Figure 1. Conceptual Model 
Note. Although psychological flexibility is a secondary outcome rather than a mediator in this 
pilot trial, our analyses will set the stage for formal mediation analyses in a future large-scale 
trial. 
